De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Glenmark Pharmaceuticals Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
Glenmark Pharmaceuticals heeft een totaal eigen vermogen van ₹78.5B en een totale schuld van ₹12.3B, wat de schuld-eigenvermogensverhouding op 15.7% brengt. De totale activa en totale passiva bedragen respectievelijk ₹143.6B en ₹65.1B. De EBIT Glenmark Pharmaceuticals is ₹16.3B waardoor de rentedekking 3.7 is. Het heeft contanten en kortetermijnbeleggingen van ₹16.6B.
Belangrijke informatie
15.7%
Verhouding schuld/eigen vermogen
₹12.31b
Schuld
| Rente dekkingsratio | 3.7x |
| Contant | ₹16.59b |
| Aandelen | ₹78.48b |
| Totaal verplichtingen | ₹65.11b |
| Totaal activa | ₹143.59b |
Recente financiële gezondheidsupdates
Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20Recent updates
This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50
Sep 06Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 06Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( ₹74.3B ) GLENMARK } overtreffen de korte termijn passiva ( ₹58.2B ).
Langlopende schulden: De kortetermijnactiva GLENMARK ( ₹74.3B ) overtreffen de langetermijnschulden ( ₹6.9B ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: GLENMARK heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van GLENMARK is de afgelopen 5 jaar gedaald van 64.7% naar 15.7%.
Schuldendekking: De operationele kasstroom van GLENMARK is negatief, waardoor de schuld niet goed gedekt is.
Rentedekking: De rentebetalingen op de schuld van GLENMARK worden goed gedekt door EBIT ( 3.7 x dekking).